- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04674020
Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment (REFORM)
December 18, 2021 updated by: Messoud Ashina, Danish Headache Center
Registry for Migraine - Structural and Functional Magnetic Resonance Imaging Before and After Erenumab Treatment
This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.
Study Overview
Detailed Description
Migraine is a prevalent neurological disorder and a leading cause of years lived with disability worldwide.
As of recent, therapies targeting calcitonin gene-related peptide (e.g.
erenumab) have been approved for the preventive treatment of migraine.
This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Messoud Ashina, MD
- Phone Number: +45 38 63 33 85
- Email: ashina@dadlnet.dk
Study Contact Backup
- Name: Hakan Ashina, MD
- Phone Number: +45 38 63 20 61
- Email: ashinajudo@yahoo.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2600
- Recruiting
- Danish Headache Center
-
Contact:
- Messoud Ashina, MD
- Phone Number: +45 38 63 33 85
- Email: ashina@dadlnet.dk
-
Contact:
- Faisal Amin, MD
- Phone Number: +45 38 63 31 86
- Email: amin.faisal@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Criteria:
Inclusion Criteria:
- Subject has provided informed consent prior to initiation of any study-specific activities/procedures
- Age greater than or equal to 18 years upon entry into screening
- History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self report
- Greater than or equal to 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening after baseline period
- Must have demonstrated greater than or equal to 75% compliance in headache diary usage during baseline period
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria apply:
Disease Related
- Greater than 50 years of age at migraine onset
- History of cluster headache or hemiplegic migraine headache
- Inability to differentiate between migraine from other headaches
- The subject is at risk of self-harm or harm to others as evidenced by past suicidal behaviour
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Prior/Concomitant Therapy
- Previously received erenumab (Aimovig®)
- Received an anti-CGRP monoclonal antibody within 3 months prior to the start of the baseline period Prior/Concurrent Clinical Study Experience
- Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study (ies). Other investigational procedures while participating in this study are excluded.
Other Exclusions
- Female subjects of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test.
- Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product.
- Female subjects of childbearing potential unwilling to use 1 acceptable method of effective contraception during treatment and for an additional 16 weeks after the last dose of investigational product.
- Evidence of current pregnancy or breastfeeding per subject self-report or medical records
- Subject has known sensitivity to any of the products or components to be administered during dosing
- Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge
Contraindications to MRI:
- Does not wish to be informed about unexpected MRI findings
- Severe claustrophobia
- Implanted magnetic material including pacemaker, prothesis, metal-clips, etc.
- Insulin pump which cannot be removed
- Magnetic foreign object in the body
- Surgical intervention within 6 weeks prior to MRI
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single-Arm
Erenumab packed in a SureClick® Autoinjector Pen (AI).
|
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Headache Diary
Time Frame: Baseline Phase (Day -42 to -28) to Month 6]
|
Headache diary with daily entries to record migraine-related data.
|
Baseline Phase (Day -42 to -28) to Month 6]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline
Time Frame: Baseline Phase (Day -42 to -28)
|
|
Baseline Phase (Day -42 to -28)
|
3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 6
Time Frame: Week 24 ± 2 Weeks
|
|
Week 24 ± 2 Weeks
|
3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 12
Time Frame: Week 48 ± 4 Weeks
|
|
Week 48 ± 4 Weeks
|
Headache Diary
Time Frame: Baseline Phase (Day -42 to -28) to Month 12
|
Headache diary with daily entries to record migraine-related data.
|
Baseline Phase (Day -42 to -28) to Month 12
|
Blood Specimen for Analysis of Biomarkers at Baseline
Time Frame: Baseline Phase (Day -42 to -28)
|
|
Baseline Phase (Day -42 to -28)
|
Blood Specimen for Analysis of Biomarkers at Month 6
Time Frame: Week 24 ± 2 Weeks
|
|
Week 24 ± 2 Weeks
|
Blood Specimen for Analysis of Biomarkers at Month 12
Time Frame: Week 48 ± 4 Weeks
|
|
Week 48 ± 4 Weeks
|
Semi-Structured Interview
Time Frame: Baseline Phase (Day -42 to -28)
|
In-person semi-structured interview to record migraine-related data.
|
Baseline Phase (Day -42 to -28)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 22, 2020
Primary Completion (Anticipated)
July 22, 2025
Study Completion (Anticipated)
July 22, 2025
Study Registration Dates
First Submitted
December 13, 2020
First Submitted That Met QC Criteria
December 13, 2020
First Posted (Actual)
December 17, 2020
Study Record Updates
Last Update Posted (Actual)
January 10, 2022
Last Update Submitted That Met QC Criteria
December 18, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Erenumab
Other Study ID Numbers
- H-20033264
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
Clinical Trials on Erenumab
-
AmgenNovartisRecruitingMigraineUnited States, Japan, Belgium, Canada, United Kingdom, Germany, Poland, Hungary, Italy, Colombia, Russian Federation, Finland, Puerto Rico
-
AmgenNovartisRecruitingMigraineUnited States, Spain, Japan, Poland, Belgium, Canada, United Kingdom, Germany, Hungary, Italy, Colombia, Russian Federation, Portugal, Switzerland, Finland, Puerto Rico
-
AmgenCompletedMigraineUnited States, Germany, Denmark, Canada, Finland, Sweden, Norway
-
AmgenCompletedMigraine HeadacheUnited States, Austria, Australia, Czechia, Finland, France, Hungary, Italy, Poland, Portugal, Spain, United Kingdom
-
Massachusetts General HospitalUnited States Department of Defense; Recordati Rare DiseasesRecruitingPain, Chronic | Schwannomatosis | SchwannomasUnited States
-
University of Maryland, BaltimoreAmgenTerminatedTrigeminal NeuropathyUnited States
-
Novartis PharmaceuticalsCompletedMigraine DisordersItaly
-
David Jang, M.D.AmgenCompleted